Comparison Between Two Definitions of Contrast-Associated Acute Kidney Injury in Patients With Congestive Heart Failure

Bo Wang, Yiying Zheng, Huanqiang Li, Shuling Chen, Ziyou Zhou, Zhubin Lun, Ming Ying, Lingyu Zhang, Ziling Mai, Liwei Liu, Ziqing Zhou, Mengfei Lin, Yongquan Yang, Jiyan Chen, Yong Liu, Jin Liu, Shiqun Chen and Ning Tan

Background: Different definitions of contrast-associated acute kidney injury (CA-AKI) have different predictive effects on prognosis. However, few studies explored the relationship between these definitions and long-term prognosis in patients with congestive heart failure (CHF). Thus, we aimed to evaluate this association and compared the population attributable risks (PAR) of different CA-AKI definitions.

Methods: This study enrolled 2,207 consecutive patients with CHF undergoing coronary angiography (CAG) in Guangdong Provincial People’s Hospital. Two different definitions of CA-AKI were used: CA-AKI_A was defined as an increase ≥0.5 mg/dl or > 25% in serum creatinine (Scr) from baseline within 72 h after CAG, and CA-AKI_B was defined as an increase of ≥0.3 mg/dl or > 50% in Scr from baseline within 48 h after CAG. Kaplan-Meier methods and Cox regression were applied to evaluate the association between CA-AKI with long-term mortality. Population attributable risk (PAR) of different definitions for long-term prognosis was also calculated.

Results: During the 3.8-year median follow-up (interquartile range 2.1-6), the overall long-term mortality was 24.9%, and the long-term mortality in patients with the definitions of CA-AKI_A and CA-AKI_B were 30.4% and 34.3%, respectively. We found that CA-AKI_A (HR: 1.44, 95% CI 1.19-1.74) and CA-AKI_B (HR: 1.48, 95% CI 1.21-1.80) were associated with long-term mortality. The PAR was higher for CA-AKI_A (9.6% vs. 8%).

Conclusions: Our findings suggested that CA-AKI was associated with long-term mortality in patients with CHF irrespective of its definitions. The CA-AKI_A was a much better definition of CA-AKI in patients with CHF due to its higher PAR. For these patients, cardiologists should pay more attention to the presence of CA-AKI, especially CA-AKI_A.

Keywords: contrast-associated acute kidney injury (CA-AKI), congestive heart failure (CHF), long-term all-cause mortality, population attributable risk (PAR), coronary angiography (CAG)
INTRODUCTION

As the common postoperative complication, contrast-associated acute kidney injury (CA-AKI) can significantly increase the risk of adverse clinical outcomes, including prolonged hospitalization, adverse cardiovascular events, renal diseases, and even long-term mortality (1–3). Previous studies proved that congestive heart failure (CHF) was an independent risk factor of CA-AKI, and patients with CHF were 1–2 times more likely to develop CA-AKI than those without CHF (4, 5).

In general, changes in plasma creatinine levels were used to diagnose the CA-AKI. The criterion is usually incremented in serum creatinine (SCr) concentration of at least 0.5 mg/dl or more than 25% within 72 h of contrast media exposure (6). However, according to some other studies, CA-AKI was confirmed as of this criterion: SCr levels increase more than 0.3 mg/dl or 50% after exposure to contrast media within 48 hours (7). A previous study found that different prevalence appeared on different definitions of CA-AKI (8). The previous study found different definition has different effect to predict long-term prognosis among patients with AMI and diabetes mellitus according to population attributable risk (PAR) (9, 10).

However, to our acknowledge, few papers evaluated the association between long-term all-cause mortality and various CA-AKI definitions among patients with CHF. Therefore, this study intended to assess the association between different CA-AKI definitions and long-term prognosis among patients with CHF receiving coronary angiography (CAG) and to determine the appropriate definition of CA-AKI in these patients.

METHOD

Study Design and Population

This study used the Cardiorenal Improvement study data, which was carried out at the largest cardiovascular center in Southern China (Guangdong Provincial People’s Hospital, China, Clinicaltrials.gov NCT04407936). The Cardiorenal Improvement study extracted demographic characteristics, comorbidities, laboratory tests, and discharge medication from the institution’s electronic medical record system. All patients received the percutaneous coronary intervention (PCI) and CAG by standard guidelines (11–14). The data quality control, as well as regular data verification, were placed in charge of senior cardiologists. The follow-up information of all patients was retrieved from the Public Security System of Guangdong province. All patients receiving CAG were screened between Jan. 1, 2007 and Dec. 31, 2018. A total of 88,938 patients received CAG, while 8,379 patients were confirmed as CHF. The flow chart including inclusion criteria and exclusion criteria of the current study was shown in Figure 1. The study protocol was developed in accordance with the Declaration of Helsinki and was authorized by the Ethics Committee of Guangdong Provincial People’s Hospital (No. GDREC2019555H[R1]).

Endpoint and Definitions

The primary study outcome was long-term all-cause mortality. CHF was defined as Killip classes II-IV or New York Heart Association (NYHA) classes III-IV (4). The definitions of CA-AKI4 and CA-AKI8 are SCr concentration increasing more than 0.5 mg/dl or 25% within 72 h postoperatively (6), and SCr level increasing more than 0.3 mg/dl or 50% within 48 h postoperatively, respectively (7). Comorbidities included coronary artery disease (CAD), acute myocardial infarction (AMI), hypertension, chronic kidney disease (CKD), anemia, diabetes mellitus, atrial fibrillation, chronic obstructive pulmonary disease (COPD), and stroke. This study used results of CAG and the 10th revision (ICD-10) of the International Classification of Diseases to determine CAD. Anemia was confirmed by gender and hematocrit (male’s hematocrit below 39% and female’s hematocrit below 36%) (15). Our study calculated the estimated glomerular filtration rate (eGFR) by applying the Modification of Diet in Renal Disease (MDRD) formula (16). The definition of CKD was eGFR ≤ 60 mL/min/1.73 m² (17, 18).

Statistical Analysis

Normally distributed data, abnormally distributed data, and categorical data are presented as mean (standard deviation [SD]), (interquartile range [IQR]), as well as number (percentage). The difference between patients with and without CA-AKI was tested by Student’s t-test, Wilcoxon rank-sum tests, and Chi-square test for continuous variables with normal distribution, continuous variables with abnormal distribution, and categorical variables. Kaplan-Meier method and log-rank test were applied to identify the prognostic differences. The association between CA-AKI and outcomes was evaluated by using the Cox proportional-hazards model, and presented as hazard ratio (HR) and 95% confidence interval (CI). Covariates included age, sex, CAD, diabetes mellitus, CKD, hypertension, hypoalbuminemia, anemia, COPD, and stroke. Two multivariate Cox regression models have been constructed for CA-AKI4 and CA-AKI8 accordingly. The PAR was calculated on the basis of the following formula: \( PAR = \frac{\text{prevalence of CA-AKI4 and CA-AKI8}}{\text{prevalence of CA-AKI4 and CA-AKI8}} \). The prevalence is the prevalence of CA-AKI4 and CA-AKI8 in our study. The present study applied the delta method to estimate the PAR’s standard error. The present study used R software (R Foundation for Statistical Computing), version 3.6.3 to carry out statistical analyses. All p-values less than.05 were considered statistically significant.

RESULT

The present study eventually enrolled 2,207 patients. Table 1 showed the baseline characteristics. In general, the mean age was 64.3 ± 10.7 years, and 68.7% of the patients were male. The number of patients complicated with CAD, hypertension, diabetes mellitus, and CKD was 1,529 (69.3%), 1,090 (49.4%), 6,92 (31.4%), and 995 (45.1%), respectively. A total of 1,153

Abbreviations: CHF, congestive heart failure; CAG, coronary angiography; CAD, coronary artery disease; PAR, population attributable risk; PCI, percutaneous coronary intervention; AMI, previous acute myocardial infarction; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; CI, confidence interval.
(52.2%) patients underwent PCI. The mean of eGFR was 63.3 ± 27.1 mL/min/1.73 m².

According to the CA-AKI_A criteria, CA-AKI occurred in 530 patients (24%), while according to the CA-AKI_B, CA-AKI occurred in 397 patients (18%). Results of demographic characteristics showed that patients with CA-AKI_B were younger compared with patients without CA-AKI_B. However, there was no significant difference in age between patients with and without CA-AKI_A. Additionally, patients with CA-AKI_A were less often male. About comorbidities, irrespective of the definition used, patients with CA-AKI complications following CAG had lower proportions of CAD, AMI, and PCI. However, patients with CA-AKI_A had a higher incidence of anemia, atrial fibrillation, and better renal function. Furthermore, the usage of renin-angiotensin system inhibitor (RASi), β-blocker, and statins in patients with CA-AKI was lower, regardless of the definition of CA-AKI.

The long-term all-cause mortality was 24.9% during the follow-up period, whose median was 3.8 (IQR 2.1-6) years. Among patients with CA-AKI_A or CA-AKI_B, the mortalities were 30.4% and 34.3%, respectively. Kaplan-Meier curves illustrate that those patients developing CA-AKI had a worse prognosis, irrespective of the CA-AKI definition (Figure 2).

Table 2 displayed the results of the univariate and multivariate cox regression. After adjusting for confounders, CA-AKI was associated with a worse prognosis. Both CA-AKI_A and CA-AKI_B could increase the risk of long-term death by 44 and 48%, (adjusted HR 1.44, 95% CI 1.19–1.74; adjusted HR 1.48, 95% CI 1.21–1.80). By evaluating the performance of the two multivariable models including CA-AKI_A and CA-AKI_B, the C-statistic showed no significant difference between the two models (0.659 vs. 0.660; p = 0.55; Table 3). The prevalence of CA-AKI_A was higher (24% vs. 18%). For the PAR, it was also higher for CA-AKI_A (PAR: 9.6%, CI: 4.4-15.1%). The PAR for CA-AKI_B was 8% (CI: 3.6-12.6%) (Figure 3).

**DISCUSSION**

Our study is the first to assess the relation between CA-AKI and long-term prognosis among patients with CHF undergoing CAG and compare the PAR of two different CA-AKI definitions. According to our findings, we found that patients developing CA-AKI had a lower survival rate. The mortality of CA-AKI_A was lower than that of CA-AKI_B, but the prevalence was higher. After adjusting for demography and baseline comorbidities, both CA-AKI_A and CA-AKI_B could increase the risk of all-cause mortality. Comprehensively considering the HR and incidence, CA-AKI_A had a higher PAR, suggesting that the definition of CA-AKI_A was more suitable for patients with CHF.

Previous studies demonstrated that both CA-AKI_A and CA-AKI_B were associated with poor long-term outcomes. Sun et al. explored the impact of CA-AKI_A on all-cause long-term mortality in 696 patients with AMI undergoing PCI (19). They demonstrated that CA-AKI_A independently predicted long-term mortality following PCI. The CA-AKI_A increases the risk of all-cause death by 1.97 times. According to Centola et al.'s study,
enrolling 406 patients who were complicated with ST-segment elevation myocardial infarction (STEMI) and underwent primary PCI treatment, results detected a significant association between two CA-AKI definitions and poor clinical outcomes (8).

The CHF was an established risk factor of CA-AKI (4, 5). The CHF patients were at high risk of CA-AKI. Compared with the general population, patients with CHF had a significantly higher incidence of CA-AKI. The result of our study found that the PAR of CHF was higher. In contrast, the result of our study found that the PAR of CHF was higher.

To evaluate the relation between CA-AKI and long-term all-cause mortality, this study firstly applied the Kaplan-Meier method to observe the differences in prognosis. Then, Cox proportional hazard models were applied to adjust confounders.

### TABLE 1 | Baseline characteristics.

| Characteristic* | Overall (n = 2,207) | Non-CA-AKI (n = 1,677) | CA-AKI A (n = 530) | P value | Non-CA-AKI B (n = 1,810) | CA-AKI B (n = 397) | P value |
|-----------------|---------------------|------------------------|------------------|--------|------------------------|-------------------|--------|
| **Demographic characteristics** |                     |                        |                  |        |                        |                   |        |
| Age, year       | 64.3 (10.7)         | 64.2 (10.8)            | 64.6 (10.3)      | 0.44   | 64.1 (10.7)            | 65.4 (10.5)       | 0.03   |
| Age ≥ 75 years, n (%) | 416 (18.9)          | 321 (19.1)             | 95 (17.9)        | 0.58   | 332 (18.3)             | 84 (21.2)         | 0.22   |
| Male, n (%)     | 1,517 (68.7)        | 1,210 (72.2)           | 307 (57.9)       | <0.001 | 1,259 (68.6)           | 258 (65.0)        | 0.09   |
| **Coexisting conditions** |                     |                        |                  |        |                        |                   |        |
| CAD, n (%)      | 1,529 (69.3)        | 1,234 (73.6)           | 295 (55.7)       | <0.001 | 1,277 (70.6)           | 252 (63.5)        | 0.007  |
| PCI, n (%)      | 1,153 (52.2)        | 952 (56.8)             | 201 (37.9)       | <0.001 | 984 (54.4)             | 169 (42.6)        | <0.001 |
| AMI, n (%)      | 796 (36.1)          | 663 (39.5)             | 133 (25.1)       | <0.001 | 689 (38.1)             | 107 (27.0)        | <0.001 |
| Hypertension, n (%) | 1,090 (49.4)       | 854 (50.9)             | 236 (44.5)       | 0.01   | 890 (49.2)             | 200 (50.4)        | 0.70   |
| Diabetes mellitus, n (%) | 692 (31.4)       | 537 (32.0)             | 155 (29.3)       | 0.25   | 559 (30.9)             | 133 (33.5)        | 0.34   |
| CKD, n (%)      | 995 (45.1)          | 773 (46.1)             | 222 (41.9)       | 0.1    | 779 (43.0)             | 216 (54.4)        | <0.001 |
| Anemia, n (%)   | 1,056 (48.0)        | 758 (45.4)             | 286 (56.2)       | <0.001 | 812 (45.0)             | 244 (61.5)        | <0.001 |
| Hypoalbuminemia, n (%) | 1245 (57.7)   | 961 (58.1)             | 284 (56.2)       | 0.47   | 1008 (57.0)            | 237 (60.6)        | 0.21   |
| Atrial fibrillation, n (%) | 387 (17.5)   | 252 (15.0)             | 135 (25.5)       | <0.001 | 300 (16.6)             | 87 (21.9)         | 0.01   |
| COPD, n (%)     | 33 (1.5)            | 27 (1.6)               | 6 (1.1)          | 0.56   | 29 (1.6)               | 4 (1.0)           | 0.51   |
| Stroke, n (%)   | 183 (8.3)           | 130 (7.8)              | 53 (10.0)        | 0.12   | 136 (7.5)              | 47 (11.8)         | 0.006  |
| **Laboratory examination** |                     |                        |                  |        |                        |                   |        |
| Total cholesterol, mmol/L | 4.5 (1.2)      | 4.5 (1.2)              | 4.6 (1.1)        | 0.08   | 4.5 (1.2)              | 4.6 (1.2)         | 0.15   |
| HDL-C, mmol/L   | 1.0 (0.3)           | 1.0 (0.3)              | 1.0 (0.3)        | <0.001 | 1.0 (0.3)              | 1.0 (0.3)         | 0.27   |
| LDL-C, mmol/L   | 2.9 (1.0)           | 2.9 (1.0)              | 2.9 (1.0)        | 0.56   | 2.9 (1.0)              | 2.9 (1.0)         | 0.37   |
| Albumin, g/L    | 33.8 (4.9)          | 33.8 (4.7)             | 33.9 (5.4)       | 0.77   | 34.0 (4.8)             | 33.3 (5.5)        | 0.01   |
| eGFR, ml/min/1.73 m² | 63.3 (27.1)   | 62.3 (25.8)            | 66.6 (30.5)      | 0.001  | 64.4 (26.5)            | 58.2 (29.1)       | <0.001 |
| **Medicine**    |                     |                        |                  |        |                        |                   |        |
| RASi, n (%)     | 797 (39.2)          | 680 (42.7)             | 117 (26.4)       | <0.001 | 712 (41.5)             | 85 (26.5)         | <0.001 |
| β-blocker, n (%) | 1,420 (69.7)       | 1,163 (73.0)           | 257 (58.0)       | <0.001 | 1,224 (71.4)           | 196 (61.1)        | <0.001 |
| Statins, n (%)  | 1,373 (67.4)        | 1,157 (72.8)           | 216 (48.7)       | <0.001 | 1,189 (69.3)           | 184 (57.3)        | <0.001 |
| **Event**       |                     |                        |                  |        |                        |                   |        |
| Long-term all-cause death, n (%) | 549 (24.9) | 388 (23.1)             | 161 (30.4)       | 0.001  | 413 (22.8)             | 136 (34.3)        | <0.001 |

*Data are presented as the mean value (standard deviation), median [interquartile range], or a number of participants (percentage).

CAD, coronary artery disease; PCI, percutaneous coronary intervention; AMI, acute myocardial infarction; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RASi, renin-angiotensin system inhibitor.
FIGURE 2 | Cumulative incidence of all-cause death for two different contrast-associated acute kidney injury (CA-AKI) definitions patients with congestive heart failure (CHF). (A) Definition of CA-AKI<sub>A</sub>, (B) Definition of CA-AKI<sub>B</sub>. 
suitable for patients with CHF to assess the relation between CA-AKI and prognosis than CA-AKI

and manage high-risk patients with CHF, who are also suffering

CKD 2.06 1.74–2.45

is an independent risk factor of long-term all-cause mortality among CHF patients and that the definition of CA-AKI is

Hypertension

Diabetes mellitus 1.48 1.25–1.76

the enrolled patients in the present study were patients with CHF, regardless of the definition. The CA-AKI definition was determined as appropriate for patients with CHF. This helps clinicians confirm and manage high-risk patients with CHF, who are also suffering

AmI 0.98 0.83–1.17

Hypothyroidism

Hypertension 1.45 1.22–1.71

Long-term all-cause mortality

Next, the incidence of different CA-AKI definitions was also considered. Combining HR and morbidity, PAR was finally calculated to assess the contribution of two different definitions to long-term all-cause death. The present study demonstrated that the PAR of CA-AKI A was higher, which indicate that among patients with CHF, the definition of CA-AKI A was at higher risk, and the method of PAR, which is comprehensively considered a relative risk and prevalence guide to clinical practice, is worth popularizing for the direction of clinical practice.

The CA-AKI has multiple definitions that confuse clinicians about the diagnosis (25). The present study found that CA-AKI is an independent risk factor of long-term all-cause mortality among CHF patients and that the definition of CA-AKI A is more suitable for patients with CHF to assess the relation between CA-AKI and prognosis than CA-AKI B. This helps clinicians confirm and manage high-risk patients with CHF. In clinical practice, more attention should be paid to patients developing CA-AKI A.

LIMITATION

There were several limitations in this study. In the first place, the enrolled patients in the present study were patients with CHF, which may not be extrapolated to the general population, whereas our study is the first one evaluating the relation between different CA-AKI definitions and long-term all-cause deaths in these patients. Second, the data in our analysis was just from a single-center, retrospective, and observational study. Nonetheless, this center was the largest cardiac intervention center in South China. Third, it’s hard to identify the progression of renal insufficiency, while some SCr data were missing during the follow-up, which may affect the results of this study. However, the present study included variables that were significantly associated with prognosis as covariates in the multivariate Cox regression analysis.

CONCLUSION

Our findings proved that CA-AKI had an association with long-term all-cause mortality among patients who suffered CHF, regardless of the definition. The CA-AKI A definition was determined as appropriate for patients with CHF. This can help cardiologists identify CA-AKI with a high risk of poor long-term prognosis among patients with CHF undergoing CAG.

| Definition of CA-AKI A | Definition of CA-AKI B | p-value |
|------------------------|------------------------|---------|
| C-statistics (95% CI)  | C-statistics (95% CI)  |         |
| Long-term all-cause mortality | 0.659 | 0.635–0.684 | 0.660 | 0.636–0.684 | 0.55 |

CA-AKI A, defined as an increase ≥ 5 mg/dl or > 25% in serum creatinine (SCr) from baseline within 72 h after CAG; CA-AKI B, defined as an increase ≥ 3 mg/dl or > 50% in SCr from baseline within 48 h after CAG; CA–AKI A, defined as an increase ≥ 0.3 mg/dl or > 50% in SCr from baseline within 25% in serum creatinine (SCr) from baseline within 72 h after CAG; CA–AKI B, defined as an increase ≥ 0.3 mg/dl or > 50% in SCr from baseline within 48 h after CAG.

from CA-AKI. In clinical practice, more attention should be paid to patients developing CA-AKI A.
**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Research Ethics Committee of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences (No. GDREC2019555H[R1]). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

YL, JL, and SC had full access to data and takes responsibility for the integrity and the accuracy of the data analysis. BW, YZ, and HL: concept and design. YY: data management. BW, YZ, HL, SC, ZL, ZiyZ, MY, LZ, ZM, LL, ZiqZ, and ML: drafting of the manuscript. YL, NT, and JC: critical revision. YL and NT: final approval to publish. All authors contributed to acquisition, analysis, interpretation of data, and read and approved the final manuscript.

**FUNDING**

This study was supported by Beijing Lisheng Cardiovascular Health Foundation (LHJ20141751), National Natural Science Foundation of China (Grant Nos. 81670339 and 81970311), Guangdong Provincial Science and Technology Plan Project (2017B030314041), Guangdong Medical Science and Technology Research Fund Project (No. A2022458), and Guangdong Provincial People’s Hospital Dengfeng Project Fund (DFJH201919, DFJH2020011, and DFJH2020026).

**ACKNOWLEDGMENTS**

We acknowledge Zhiqi Su and Danyuan Xu in Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention for help in data extraction and verification.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.763656/full#supplementary-material

**REFERENCES**

1. Goldberg A, Hammerman H, Petcherski S, Zdorovaya A, Yalonetsky S, Kapeliovich M et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. *Am Heart J.* (2005) 1502:330–7. doi: 10.1016/j.ahj.2004.09.055

2. Mitchell AM, Kline JA, Jones AE, Tumlin JA. Major adverse events one year after acute kidney injury after contrast-enhanced computed tomography. *Ann Emerg Med.* (2015) 663:267–274.e264. doi: 10.1016/j.annemergmed.2015.04.028

3. Sato A, Aonuma K, Watanabe M, Hirayama A, Tamaki N, Tsutsui H et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: from the CINC-J study. *Int J Cardiol.* (2017) 227:424–9. doi: 10.1016/j.ijcard.2016.11.019

4. Mehran R, Nikolsky E, Reimer P, Webb JA, Thomsen HS, Morcos SK et al. Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. *Eur Radiol.* (2011) 2112:2527–41. doi: 10.1007/s00330-011-2225-0

5. Abe D, Sato A, Hoshi T, Kakefuda Y, Watabe H, Ojima E et al. Clinical predictors of contrast-induced acute kidney injury in patients undergoing emergency versus elective percutaneous coronary intervention. *Circ J.* (2014) 781:85–91. doi: 10.1253/circj.cj-13-0574

6. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK et al. Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. *Eur Radiol.* (2011) 2112:2527–41. doi: 10.1007/s00330-011-2225-0

7. Moriyama N, Ishihara M, Noguchi T, Nakanishi M, Arakawa T, Asaumi Y et al. Admission hyperglycemia is an independent predictor of acute kidney injury in patients with acute myocardial infarction. *Circ J.* (2014) 786:1475–80. doi: 10.1253/circj.cj-14-0117

8. Centola M, Lucrezio T, Salerno-Uriaite D, Sponzilli C, Ferrante G, Acquaviva R et al. A comparison between two different definitions of coronary intervention: development and initial validation. *J Am Coll Cardiol.* (2004) 447:1393–9. doi: 10.1016/j.jacc.2004.06.068
of contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. (2016) 210:4–9. doi: 10.1016/j.ijcard.2016.02.086
9. Lei L, Xue Y, Guo Z, Liu B, He Y, Song F et al. A comparison between different definitions of contrast-induced acute kidney injury for long-term mortality in patients with acute myocardial infarction. Int J Cardiol Heart Vasc. (2021) 28:100522. doi: 10.1016/j.ijcheart.2021.100522
10. Lun Z, Lei L, Zhou D, Ying M, Liu L, Chen G et al. A comparison between two different definitions of contrast-associated acute kidney injury for long-term mortality in patients with diabetes undergoing coronary angiography: a prospective cohort study. BMC Cardiovasc Disord. (2020) 201:485. doi: 10.1186/s12872-020-01778-6
11. Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Antman et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) (update) of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2009) 5423-2205–41. doi: 10.1016/j.jacc.2009.10.015
12. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2012) 607:645–81. doi: 10.1016/j.jacc.2012.06.004
13. Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J. (2014) 3546:3235–6. doi: 10.1093/eurheartj/ehu422
14. Neumann FJ, Sousa-Uva M, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. (2018) 35:2567–311. doi: 10.1093/eurheartj/ehy394
15. Nutrition and Diet. Report of a WHO scientific group. World Health Organ Tech Rep Ser. (1968) 405:5–37.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D A. more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. (1999) 1306:461–70. doi: 10.7326/0003-4819-130-6-199903160-00002
17. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. (2002) 39:2S–1S.
18. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. (2003) 41:47–55. doi: 10.1016/j.ijcard.2017.02.0263-3
19. Sun GL, Lei L, Liu L, Liu I, He Y, Guo Z et al. Rationale and design of the Web-basEd soCaI media tecHnology to improvement in Adherence to dual anIpltateTherapy following Drug-EIuting Stent Implantation (WECHAT): protocol for a randomised controlled study. BMJ Open. (2020) 101:e033017. doi: 10.1136/bmjopen-2019-033017
20. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR CathPCI registry. JACC Cardiovasc Interv. (2014) 71:1–9. doi: 10.1016/j.jcin.2013.06.016
21. Chen SQ, Liu Y, Bei WJ, Wang Y, Duan CY, Wu DX et al. Optimal hydration volume among high-risk patients with advanced congestive heart failure undergoing coronary angiography. Oncotarget. (2018) 934:23738–48. doi: 10.18632/oncotarget.25315
22. Lei L, Huang Y, Guo Z, Song F, He Y, Liu J et al. Impact of contrast-induced acute kidney injury on the association between renin-angiotensin system inhibitors and long-term mortality in heart failure patients. J Renin Angiotensin Aldosterone Syst. (2020) 214:170320320979795. doi: 10.1177/170320320979795
23. Bei WJ, Wang K, Li HL, Lin KY, Guo XS, Chen SQ et al. Safe hydration volume to prevent contrast-induced acute kidney injury and worsening heart failure in patients with heart failure and preserved ejection fraction after cardiac catheterization. J Cardiovasc Pharmacol. (2017) 703:168–75. doi: 10.1097/fjc.0000000000000502
24. Wang K, Li HL, Chen LL, Bei WJ, Lin KY, Smyth B et al. Association of N-terminal pro-brain natriuretic peptide with contrast-induced acute kidney injury and long-term mortality in patients with heart failure and mid-range ejection fraction: An observation study. Medicine (Baltimore). (2017) 9610:e2659. doi: 10.1097/md.0000000000006259
25. Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther. (2016) 302:215–28. doi: 10.1007/s10557-015-6635-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Zheng, Li, Chen, Zhou, Lan, Ying, Zhang, Mai, Liu, Zhou, Lin, Yang, Chen, Liu, Liu, Chen and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.